Cassava Sciences Swings to $67.6M Loss Amid R&D Cuts

TL;DR

**SAVA is burning cash and cutting R&D, signaling a tough road ahead for its drug pipeline and a likely continued stock slide.**

AI Summary

Cassava Sciences, Inc. reported a significant net loss of $67.6 million for the six months ended June 30, 2025, a substantial decline from the net income of $31.2 million in the same period of 2024. This shift was primarily driven by the absence of a 'Gain from change in fair value of warrant liabilities,' which contributed $108.2 million to net income in the prior year. Operating expenses decreased to $69.9 million for the six months ended June 30, 2025, down from $81.3 million in 2024, largely due to a reduction in research and development expenses from $31.4 million to $18.8 million. General and administrative expenses remained relatively stable at $51.2 million in 2025 compared to $49.9 million in 2024. The company's cash and cash equivalents decreased from $128.6 million at December 31, 2024, to $112.4 million at June 30, 2025, with net cash used in operating activities totaling $16.3 million for the first six months of 2025, a notable improvement from $37.4 million used in the same period of 2024. The accumulated deficit grew to $472.7 million as of June 30, 2025, up from $405.1 million at December 31, 2024.

Why It Matters

This filing reveals a significant financial downturn for Cassava Sciences, shifting from a net income of $31.2 million to a net loss of $67.6 million year-over-year. For investors, this signals increased burn rate and reliance on existing cash reserves, especially with cash and cash equivalents dropping to $112.4 million. The substantial reduction in R&D spending, from $31.4 million to $18.8 million, could impact the pace of drug development, potentially delaying critical clinical trial milestones and affecting future product pipeline competitiveness against rivals in the nervous system disorder space. Employees might face uncertainty regarding future project funding, while customers awaiting new treatments could see longer development timelines. The broader market will watch how this biotech navigates its financial challenges while pursuing drug development.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $472.7 million at June 30, 2025, and a net loss of $67.6 million for the six months ended June 30, 2025. Cash and cash equivalents decreased by $16.2 million to $112.4 million, indicating a significant cash burn rate without product revenue, posing a high risk to sustained operations without further financing.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to SAVA. The significant net loss and declining cash position, coupled with reduced R&D spending, suggest a challenging financial outlook and potential delays in product development. Monitor future financing activities closely.

Financial Highlights

debt To Equity

0.54

revenue

N/A

operating Margin

N/A

total Assets

$135,384,000

total Debt

$47,411,000

net Income

-$67,627,000

eps

-$1.40

gross Margin

N/A

cash Position

$112,381,000

revenue Growth

N/A

Key Numbers

• $67.6M — Net Loss (for six months ended June 30, 2025, compared to $31.2M net income in 2024)
• $112.4M — Cash and Cash Equivalents (at June 30, 2025, down from $128.6M at Dec 31, 2024)
• $18.8M — Research and Development Expenses (for six months ended June 30, 2025, a decrease from $31.4M in 2024)
• $472.7M — Accumulated Deficit (at June 30, 2025, up from $405.1M at Dec 31, 2024)
• $16.3M — Net Cash Used in Operating Activities (for six months ended June 30, 2025, an improvement from $37.4M in 2024)
• 48,307,896 — Common Shares Outstanding (as of August 12, 2025)
• $0.92 — Net Loss Per Share, Basic (for three months ended June 30, 2025, compared to $0.13 net income per share in 2024)

Key Players & Entities

• Cassava Sciences, Inc. (company) — registrant of the 10-Q filing
• $67.6 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $31.2 million (dollar_amount) — net income for the six months ended June 30, 2024
• $108.2 million (dollar_amount) — gain from change in fair value of warrant liabilities in 2024
• $18.8 million (dollar_amount) — research and development expenses for six months ended June 30, 2025
• $31.4 million (dollar_amount) — research and development expenses for six months ended June 30, 2024
• $112.4 million (dollar_amount) — cash and cash equivalents at June 30, 2025
• $128.6 million (dollar_amount) — cash and cash equivalents at December 31, 2024
• $472.7 million (dollar_amount) — accumulated deficit at June 30, 2025
• Nasdaq Capital Market (regulator) — exchange where common stock is registered

FAQ

Risk Factors

• Significant Net Loss and Accumulated Deficit [high — financial]: The company reported a net loss of $67.6 million for the six months ended June 30, 2025, a stark contrast to the $31.2 million net income in the prior year. This deterioration is primarily due to the absence of a $108.2 million gain from the change in fair value of warrant liabilities. The accumulated deficit has grown to $472.7 million as of June 30, 2025, indicating a substantial historical loss.
• Decreased R&D Spending [medium — operational]: Research and development expenses were reduced to $18.8 million for the first six months of 2025, down from $31.4 million in the same period of 2024. While this contributed to lower operating expenses, a significant reduction in R&D could impact future product development and pipeline progression.
• Declining Cash Position [medium — financial]: Cash and cash equivalents decreased from $128.6 million at the end of 2024 to $112.4 million by June 30, 2025. The company used $16.3 million in net cash from operations during the first half of 2025, which, while an improvement from the prior year's $37.4 million usage, still represents a cash burn.
• Dependence on Clinical Trial Success [high — regulatory]: As a clinical-stage biotechnology company, Cassava Sciences is heavily reliant on the successful outcome of its ongoing clinical trials for its drug candidates. Any setbacks, delays, or failures in these trials could have a material adverse effect on the company's financial condition and prospects.
• Competition in Alzheimer's Disease Treatment [high — market]: The market for Alzheimer's disease treatments is highly competitive, with numerous pharmaceutical companies developing and marketing therapies. The success of Cassava Sciences' lead drug candidate, simufilam, will be measured against existing and emerging treatments, requiring significant differentiation and efficacy.
• Need for Future Financing [high — financial]: Given the ongoing net losses and cash burn, Cassava Sciences will likely require additional capital to fund its operations, clinical trials, and potential commercialization efforts. Future financing may be dilutive to existing shareholders or subject to market conditions.
• Reliance on Key Personnel [medium — operational]: The company's success depends on its ability to attract and retain highly qualified scientific and management personnel. The loss of key individuals could disrupt research, development, and strategic operations.
• Potential Litigation and Intellectual Property Disputes [medium — legal]: Biotechnology companies are often subject to intellectual property disputes and potential litigation related to drug development and patent protection. Such legal challenges can be costly and time-consuming, impacting the company's resources and strategic focus.

Industry Context

Cassava Sciences operates in the highly competitive biotechnology sector, specifically focusing on treatments for neurodegenerative diseases like Alzheimer's. The industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the potential for substantial rewards if successful therapies are brought to market. Key trends include advancements in understanding disease mechanisms and the development of novel therapeutic approaches.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Cassava Sciences is subject to stringent regulatory oversight from bodies like the FDA. The success of its drug candidates hinges on successful clinical trials and subsequent regulatory approval. Any delays, adverse findings, or failure to meet regulatory standards can severely impact the company's prospects and financial health.

What Investors Should Do

1. Monitor R&D spending and clinical trial progress closely.
2. Assess the sustainability of operations given the cash burn.
3. Evaluate the impact of the absence of warrant liability gains on future earnings.
4. Consider the competitive landscape and market penetration potential.

Key Dates

• 2025-06-30: Six Months Ended — Period of significant net loss ($67.6M) and reduced R&D expenses ($18.8M).
• 2025-06-30: Balance Sheet Date — Cash and cash equivalents stood at $112.4M, with total assets of $135.4M and total liabilities of $47.4M.
• 2024-12-31: Year End Balance Sheet — Cash and cash equivalents were $128.6M, with total assets of $157.5M and total liabilities of $11.8M.
• 2024-06-30: Six Months Ended — Period of net income ($31.2M), significantly boosted by a $108.2M gain from warrant liabilities.
• 2025-08-12: Common Shares Outstanding — Reported 48,307,896 shares outstanding, indicating minimal change from the previous period.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total losses incurred since the company's inception. (Shows the company's long-term profitability, which is currently negative and growing, standing at $472.7 million as of June 30, 2025.)

Gain from change in fair value of warrant liabilities

An accounting adjustment reflecting the change in the estimated market value of outstanding warrants issued by the company. This can be a significant non-cash item affecting net income. (This item was a major driver of net income in the prior year ($108.2 million) but was absent in the current period, explaining a large portion of the net loss.)

Operating expenses

The costs incurred by a company in its normal business operations, excluding costs of goods sold. This includes research and development, and general and administrative expenses. (Total operating expenses decreased to $69.9 million for the six months ended June 30, 2025, primarily due to reduced R&D spending.)

Net cash used in operating activities

The amount of cash a company has spent on its core business operations during a period. A negative number indicates cash outflow. (The company used $16.3 million in operating activities in the first half of 2025, an improvement from $37.4 million in the prior year, but still shows ongoing cash consumption.)

Warrant liabilities

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. They are often issued alongside other securities. (Changes in the fair value of these liabilities significantly impacted the company's net income in the prior year, highlighting the non-operational nature of past income.)

Year-Over-Year Comparison

Compared to the six months ended June 30, 2024, Cassava Sciences has shifted from a net income of $31.2 million to a net loss of $67.6 million. This reversal is largely due to the absence of a significant $108.2 million gain from the change in fair value of warrant liabilities in the current period. While operating expenses have decreased from $81.3 million to $69.9 million, driven by a reduction in R&D, the company's cash position has declined from $128.6 million to $112.4 million, and its accumulated deficit has grown substantially to $472.7 million.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SAVA Nasdaq Capital Marke

Filing Documents

• sava20250630_10q.htm (10-Q) — 985KB
• ex_824152.htm (EX-31.1) — 13KB
• ex_824153.htm (EX-31.2) — 14KB
• ex_824154.htm (EX-32.1) — 7KB
• 0001437749-25-026686.txt ( ) — 5113KB
• sava-20250630.xsd (EX-101.SCH) — 48KB
• sava-20250630_cal.xml (EX-101.CAL) — 30KB
• sava-20250630_def.xml (EX-101.DEF) — 301KB
• sava-20250630_lab.xml (EX-101.LAB) — 269KB
• sava-20250630_pre.xml (EX-101.PRE) — 328KB
• sava20250630_10q_htm.xml (XML) — 826KB

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets – June 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations – Three and Six Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Changes in Stockholders' Equity - Three and Six Months Ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows – Six Months Ended June 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 29 Item 5. Other Information 29 Item 6. Exhibits 29

Signatures

Signatures 30 2 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CASSAVA SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, In thousands, except share and par value data) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 112,381 $ 128,574 Prepaid expenses and other current assets 2,440 7,958 Total current assets 114,821 136,532 Property and equipment, net 20,563 21,001 Total assets $ 135,384 $ 157,533 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 42,822 $ 7,654 Accrued development expense 3,788 2,440 Accrued compensation and benefits 563 1,357 Other current liabilities 159 299 Total current liabilities 47,332 11,750 Other non-current liabilities 79 79 Total liabilities 47,411 11,829 Commitments and contingencies (Notes 8, 9 and 10) Stockholders' equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized, none issued and outstanding — — Common stock, $ 0.001 par value; 120,000,000 shares authorized; 48,307,896 and 48,203,179 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 48 48 Additional paid-in capital 560,663 550,767 Accumulated deficit ( 472,738 ) ( 405,111 ) Total stockholders' equity 87,973 145,704 Total liabilities and stockholders' equity $ 135,384 $ 157,533 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents CASSAVA SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Three months ended Six months ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 5,116 $ 15,198 $ 18,782 $ 31,431 General and administrative 40,276 46,204 51,196 49,905 Total operating expenses 45,392 61,402 69,978 81,336 Operating loss ( 45,392 ) ( 61,402 ) ( 69,978 ) ( 81,336 ) Interest income 1,214 2,

View Full Filing

View this 10-Q filing on SEC EDGAR